Clinical Trial Update: Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation [Phase 3]

View source ↗

Summary

Phase 3 clinical trial is currently recruiting to assess semaglutide as a metabolic intervention and adipose loss strategy for treating atrial fibrillation in a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Obesity

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: University of Chicago | Conditions: Overweight or Obesity, Atrial Fibrillation | Phase 3 | Status: RECRUITING